Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

>

Notes payable, less current portion - 119,000

Capital lease obligation, less current portion 22,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock - $.001 par value; authorized

5,000,000 shares; non-voting; nil shares

outstanding - -

Common stock - $.001 par value; authorized

325,000,000 shares; outstanding - 226,210,617

and 196,112,201, respectively 226,000 196,000

Additional paid-in-capital 246,205,000 224,453,000

Accumulated deficit (230,836,000) (207,660,000)

Total stockholders' equity 15,595,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,057,000 $22,997,000

-continued-

PEREGRINE PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2008

2008 2007 2006

REVENUES:

Contract manufacturing

revenue $5,897,000 $3,492,000 $3,005,000

License revenue 196,000 216,000 188,000

Total revenues 6,093,000 3,708,000 3,193,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 4,804,000 3,296,000 3,297,000

Research and development 18,279,000 15,876,000 12,415,000

Selling, general and

administrative 7,150,000 6,446,000 6,564,000

Total costs and

expenses 30,233,000 25,618,000 22,276,000

LOSS FROM OPERATIONS (24,140,000) (21,910,000) (19,08
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
(Date:9/19/2014)... September 19, 2014 Barnhardt Manufacturing ... Label for its Organic Cotton . The USDA ... of renewable biobased ingredients meets or exceeds levels set ... composed in whole or in significant part of agricultural, ... allow our Organic cotton to be immediately identified as ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... and Webcast on May 9 at 8:00 a.m. PDT ... Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... the three months ended March 31, 2008., "This ... significantly advanced both,our partnered and proprietary programs in the ...
... May 8 Telik, Inc. (Nasdaq:,TELK) today reported a ... for,the first quarter ended March 31, 2008, compared with ... for the comparable period in 2007., For the ... were $10.6 million, compared with $18.0 million during the ...
... to ever increasing,cardiac toxicity found in market drugs, Gwathmey ... Cardionomics(TM) services,and the formation of its Cardionomics(TM) Advisory Board ... of drug candidates., Cardiac toxicity has played a ... over the past 30 years. It is estimated that ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 First Quarter Financial Results 2Halozyme Therapeutics Reports 2008 First Quarter Financial Results 3Halozyme Therapeutics Reports 2008 First Quarter Financial Results 4Halozyme Therapeutics Reports 2008 First Quarter Financial Results 5Halozyme Therapeutics Reports 2008 First Quarter Financial Results 6Halozyme Therapeutics Reports 2008 First Quarter Financial Results 7Halozyme Therapeutics Reports 2008 First Quarter Financial Results 8Halozyme Therapeutics Reports 2008 First Quarter Financial Results 9Telik Announces First Quarter 2008 Financial Results 2Telik Announces First Quarter 2008 Financial Results 3Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 2Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 3Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 4
(Date:9/19/2014)... evolve for the sake of fairness per se but ... so say Frans de Waal, PhD, and Sarah Brosnan, ... (IA), which is defined as a negative reaction to ... . , Their conclusion comes after the co-authors ... hypothesis that it is the evolution of forestalling partner ...
(Date:9/19/2014)... -- Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" ... m-commerce market, updates the "Wocket in Your Pocket" celebrity ad campaign, ... middleweight weight classes, Vinny Pazienza (PAZ). ... of Thrones actor Ciaran Hinds and Sons ... Katey Sagal have been cast in Bleed for This ...
(Date:9/18/2014)... Wash. - Washington State University researchers have developed a ... to power waste cleanup in rural areas. , ... to an inexpensive and quick way to clean up ... plants while reducing pollution. , Professor Haluk Beyenal ... of Engineering and Architecture discuss the system in the ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2
... over face threats on many fronts: pollution, diseases, destructive fishing ... resistant to one potential menace seaweed than previously ... scientists from the United States and Australia. Their study ... individual reefs in all, more than 3,500 examinations of ...
... different species are likely to respond to climate change. ... species and the interactions between species, in the interest ... BioScience , by Eric Post of Pennsylvania State ... be avoided. Their approach, which relies on multi-stage analyses ...
... (June 1, 2009) The International Serious Adverse Events ... designed to discover genetic markers that may predict individuals ... The SAEC is a nonprofit research corporation, launched ... by 10 leading pharmaceutical companies and the Wellcome Trust. ...
Cached Biology News:In the turf war against seaweed, coral reefs more resilient than expected 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 3
... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: